The Evolut Low Risk Trial
5 min
Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.
About the show
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
Newest episodes
The BHF PROTECT-TAVI Trial
5 min
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
The FAME 3 Trial
9 min
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
Similar podcasts
All episodes
The newest 50 of 214 episodes
The Evolut Low Risk Trial
5 min
Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.
The BHF PROTECT-TAVI Trial
5 min
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
The FAME 3 Trial
9 min
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
The TRILUMINATE Pivotal Trial
8 min
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
The PRAGUE-25 Study
7 min
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
The BETAMI-DANBLOCK Trial
8 min
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI
1 hr 33 min
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
The PROCTOR Trial
8 min
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
The SELUTION DeNovo Trial
5 min
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
The VESALIUS-CV Trial
7 min
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
The META-AF Trial
4 min
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
Evolution of Pharmacotherapy in STEMI
8 min
How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
The CorCMR Trial
5 min
Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.
The TUXEDO-2 Trial
3 min
Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.
The FLOW Trial
5 min
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
The 2024 ESC CCS Guidelines
15 min
Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
The My Heart Your Heart Trial
6 min
Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.
The FAVOR III Europe Trial
14 min
Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.
The FLOW Trial
5 min
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
STORM-PE TRIAL
14 min
James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).
The EARLY TAVR and TAVR UNLOAD Trials
15 min
For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.
The EPIC-CAD Trial
14 min
Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.
The ECLIPSE Trial
7 min
Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.
The CLEAR SYNERGY (OASIS 9) Trial
7 min
Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss. 097245
The NOTION-3 Trial
17 min
Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.
TMVR in the Heart Failure Paradigm
14 min
Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.
The ABYSS Trial
6 min
Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.
Patient Selection and Treatment Goals
15 min
Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.
Women's Health Study: Biomarkers
9 min
Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
Echocardiography and Quality Data
22 min
Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.
Insights on Intrepid 2-Yr Mitral TF EFS
16 min
The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.
New ESC Guidelines for AF
20 min
Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.
The STEEER-AF Trial
5 min
Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.
The EPIC-CAD Trial
12 min
Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.
Acute Coronary Care in Ethiopia
12 min
Mamas Mamas talks to Tesfaye Telila about the landscape of acute coronary care in Ethiopa, where just a few dozen cardiologists contend with a population of 120 million people.
The POPular PAUSE TAVI Trial
4 min
Should we stop anticoagulation therapy before TAVI in patients with aortic stenosis? Dirk-Jan van Ginkel and C. Michael Gibson discuss.
The SENIOR-RITA Trial
10 min
Vijay Kunadian talks to C. Michael Gibson about using an invasive or conservative strategy for older patients with NSTEMI.
The REDUCE-AMI Trial
12 min
Troels Yndigegn, Sripal Bangalore, and Mamas Mamas discuss whether beta-blockers still benefit patients with acute MI and preserved ejection fraction.
The EARTH-STEMI Trial
6 min
Gianluca Campo and C. Michael Gibson compare complete versus culprit-only revascularization in older STEMI patients.
The SCOFF Trial
7 min
David Ferreira talks to C. Michael Gibson about the latest data showing patients don't need to fast ahead of cardiac catheterization.
The RESHAPE-HF2 and MATTERHORN Trials
16 min
Mamas Mamas, Stefan Anker, and Volker Rudolph talk about their studies of MitraClip for functional MR in patients with heart failure.
The EMPACT-MI Trial
6 min
Javed Butler and C. Michael Gibson discuss the trial testing early empagliflozin after acute MI.
The PROACT Trial
4 min
Talking with C. Michael Gibson, David Austin reviews the phase III trial of enalapril for anthracycline-induced cardiotoxicity in lymphoma and breast cancer patients.
The ORBITA-COSMIC Trial
12 min
Rasha Al-Lamee and Michael Foley sit down with Mamas Mamas to discuss data on an implantable coronary sinus reducer that can ease symptoms in patients with refractory angina.
The REVIVED-BCIS2 Randomized Trial
6 min
Looking at the REVIVED-BCIS2 results, Divaka Perera and C. Michael Gibson discuss the relationship between myocardial viability, PCI, and outcomes.
Ketogenic Diet and Cardiovascular Risk
6 min
Iulia Iatan talks to C. Michael Gibson about how a low-carbohydrate, high-protein diet can increase plasma lipid levels and cardiovascular risk.
The CLEAR Outcomes Trial
7 min
Steven Nissen and C. Michael Gibson discuss using bempedoic acid to reduce MACE in statin-intolerant patients with high cardiovascular risk.
Inflammatory Risk in Statin-Treated Patients
11 min
Pooling data from the PROMINENT, REDUCE-IT, and STRENGTH trials, Paul Ridker and C. Michael Gibson discuss the residual inflammatory risks for patients treated with statins.
The BUDAPEST CRT Upgrade Trial
12 min
Béla Merkely and C. Michael Gibson discuss the results of a CRT-D upgrade versus ICD alone for HFrEF patients with right ventricular pacing.
The HEART-FID Trial
4 min
Robert Mentz and C. Michael Gibson discuss the latest trial to address whether iron supplementation, this time with ferric carboxymaltose, improves outcomes for patients with HF and iron deficiency.
–
0 ratings from members
5
4
3
2
1
Rate this podcast
Log in to rate and review the shows you listen to.
No reviews yet — be the first member to rate "Talking Points".
This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.
Keep listening